Studies show that the Th17/IL-17A axis plays an important role in the pathogenesis of kidney diseases. Previously, we also showed that IL-17A may play a role in the pathogenesis of primary nephrotic syndrome; however, the underlying mechanism(s) is unclear. The aim of this study was to explore the molecular mechanism of IL-17A-inducing podocyte injury in vitro. In this study, the NLRP3 inflammasome activation and the morphology of podocytes were detected by Western blot and immunofluorescence. The results showed that podocytes persistently expressed IL-17A receptor and that NLRP3 inflammasome in these cells was activated upon exposure to IL-17A. Also, activity of caspase-1 and secretion of IL-1b increased in the presence of IL-17A. In addition, IL-17A disrupted podocyte morphology by decreasing expression of podocin and increasing expression of desmin. Blockade of intracellular ROS or inhibition of caspase-1 prevented activation of the NLRP3 inflammasome, thereby restoring podocyte morphology. Taken together, the results suggest that IL-17A induces podocyte injury by activating the NLRP3 inflammasome and IL-1b secretion and contributes to disruption of the kidney's filtration system.
| INTRODUCTION
Studies show that the Th17/IL-17A axis plays an important role in the pathogenesis of chronic kidney disease (CKD). [1] [2] [3] IL-17A is a crucial proinflammatory cytokine that acts as an important node connecting the innate and adaptive immune systems. It recruits neutrophils to the kidney and contributes to the formation of an inflammatory milieu by stimulating mesangial cells and tubular epithelial cells to secrete chemokines and other proinflammatory mediators. 4 Primary nephrotic syndrome (PNS) is a chronic inflammatory disease in which the Th17/IL-17 axis plays a role by promoting podocyte apoptosis via caspase-8-caspase-3-Fas/FasL signalling. 5, 6 Moreover, IL-17A induced production of c-mip and increased the binding of c-mip to NF-jB/RelA during adriamycininduced podocyte damage. 7 However, the mechanism by which IL-17A causes podocyte injury is still obscure.
The Nod-like receptor protein 3 (NLRP3) inflammasome is a multiprotein complex comprising the NLRP3 protein, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and procaspase-1. The NLRP3 inflammasome is an important component of the innate immune response and plays a crucial role in the maturation and secretion of IL-1b and IL-18. 8, 9 Recent studies show that the activation of the NLRP3 inflammasome plays a role in the pathogenesis of kidney diseases such as diabetic nephropathy and hyperhomocysteinemia. 10, 11 However, few studies have examined the role of the NLRP3 inflammasome activation in podocyte injury during immune-related kidney disease. As both the Th17/IL-17A axis and NLRP3 inflammasome activation appear to be associated with the pathogenesis of immune-related kidney disease, we speculate that IL-17A might induce podocyte injury by activating the NLRP3 inflammasome. Here, we show NLRRP3 inflammasome was activated in the presence of IL-17A and IL-17A could disrupt the morphology of podocytes in vitro. Moreover, podocyte injury was prevented by blocking activation of the NLRP3 inflammasome. Taken together, the results suggest that IL-17A plays a role in podocyte injury by inducing secretion of IL-1b via activation NLRP3 inflammasome.
| MATERIALS AND METHODS

| Materials
Recombinant mouse IL-17A was obtained from Peprotech (Rocky Hill, USA). Caspase-1 inhibitor (Z-YVAD-fmk) was purchased from Biovision (San Francisco, USA). The IL-17 receptor antibody was obtained from R&D Systems (Minneapolis, USA).Anti-podocin, anti-caspase-1, anti-NLRP3 and anti-IL-17A antibodies were obtained from Abcam (Cambridge, UK). The anti-desmin and anti-GAPDH antibodies were obtained from Proteintech (Wuhan, China). The anti-IL-1b was purchased from Santa Cruz (TX, USA).
| Cell culture and treatments
Conditional immortalized mouse podocytes were a gift from Professor P. Mundel (Mount Sinai School of Medicine) and were obtained through Professor Zhuo Yang (Nankai University). Cells were cultured as previously described. 12 In brief, podocytes were placed in culture dishes coated with 0.1 mg/mL rat tail collagen type I (Millipore) and gown under permissive conditions at 33°C in RPMI 1640 medium supplemented with 10% foetal bovine serum and 20 U/mL recombinant murine IFN-c (315-05; Peprotech). Podocyte differentiation was induced by culture in RPMI medium 1640 at 37°C for 10-14 days in the absence of recombinant murine IFN-c. Cells were then divided into 5 groups (a control group, an IL-17A-treated group, an IL-17A + IL-17RA-treated group, an IL-17A + NAC-treated group and an IL-17A + Z-YVADfmk-treated group). The IL-17A group was treated with IL-17A (100 ng/mL) for 48 hours. Cells were exposed to IL-17RA, NAC or Z-YVAD-fmk for 1 hour before exposure to IL-17A for 48 hours.
| Reverse transcription-PCR and realtime PCR
Total RNA was extracted from cells using an RNA extraction kit (BioTeke, Beijing, China), according to the manufacturer's instructions. The RNA was then reverse transcribed using a PrimeScript â RT Reagent Kit with gDNA Eraser. One-step real-time PCR was conducted with primers specific for GAPDH (forward 
| Flow cytometry
To measure IL-17A receptor expression, podocytes were digested with 0.05% trypsin in PBS and the resulting cell suspension was divided into 2 aliquots: one aliquot was analysed for IL-17A receptor (CD217) expression and the other was used as an isotype control. Cells were incubated with an anti-CD217-APC or isotype control antibody for 30 minutes in the dark, washed twice with 0.01 mol/L PBS and detected with a FACScan flow cytometer (Becton Dickinson). For each group, 30 000 events were collected and the results were analysed using FlowJo software (7.6.1).
| Western blot analysis
Total protein was extracted from podocytes using RIPA buffer containing a protein inhibitor (BioTeke, Beijing, China). The protein concentration was measured using a bicinchoninic acid assay reagent kit (Beyotime, Shanghai, China). Total protein (40 lg/lane) was separated by electrophoresis on 8%-12% sodium dodecyl sulphate polyacrylamide gels (Beyotime) and then transferred to a polyvinylidene fluoride membrane (Millipore, Massachusetts, USA). The membrane was incubated for 1 hour at room temperature in 5% low-fat milk prepared in TBST buffer, followed by a specific primary antibody (diluted 1:400-1:5000 in TBST) overnight at 4°C. After washing 3 times with TBST buffer, the membrane was incubated with a horseradish peroxidase-conjugated secondary antibody (diluted 1:5000 in TBST). GAPDH was used as an internal control for each lane. The results were quantified by the analysis of grey scale images using Image J software (USA).
| Immunofluorescence staining
Differentiated podocytes were treated with IL-17A (100 ng/mL) for 48 hours, washed twice with 0.01 mol/L PBS and fixed for 15 minutes at room temperature in 4% paraformaldehyde (PFA). Cells were then permeabilized for 10 minutes in 0.3% Triton X-100 freshly prepared in 0.01 mol/L PBS and then blocked for 30 minutes with 0.5% BSA in PBS. Alexa-488-conjugated phalloidin was used to label the actin cytoskeleton. To detect caspase-1, NLRP3, podocin and desmin, cells were incubated overnight at 4°C with the appropriate primary antibody, followed by goat anti-rabbit igG H&L(FITC) for 1 hour in the dark. Nuclei were stained with DAPI. The immunofluorescence signal was detected under a fluorescence microscope (90I; Nikon, Japan).
| Enzyme-linked immunosorbent assay (ELISA)
IL-1b in the culture supernatants from podocytes was measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's recommended protocol (Neobioscience Technology Company, Shenzhen, China).
| Measurement of caspase-1 activity
Caspase-1 activity was measured using a colorimetric assay kit as recommended by the manufacturer (Applygen, Beijing, China). Caspase-1 can complete the hydrolysis of the polypeptide complex Tyr-Val-Ala-Asp-p-nitroanilide (YVAD-pNA), thereby releasing p-nitroaniline (pNA), which has maximum absorbance at 405 nm. Protein (50 lg) in a 96-well plate was incubated overnight at 37°C with 5 lL IETD-pNA (2 mmol/L). The absorbance of pNA was measured in a spectrophotometer (Varioscan Flash; Thermo Fisher Scientific Inc., USA). A standard curve was constructed using pNA standards. The amount of pNA in different samples was indicative of caspase-1 activity.
| Measurement of intracellular ROS
Intracellular ROS was measured using an oxidation-sensitive fluorescent probe (DCFH-DA). Cells were treated with IL-17A (100 ng/mL) with or without NAC (10 mmol/L for 48 hours) and washed twice in 0.01 mol/L PBS. Then, cells were incubated at 37°C for 30 minutes in the dark with 40 lmol/L DCFH-DA and washed with RPMI 1640 without foetal bovine serum in accordance with the manufacturer's protocol (Beyotime, Shanghai, China). Intracellular DCFH-DA was deacetylated by a non-specific esterase and further oxidized by ROS to yield a fluorescent compound (2, 7-dichlorofluorescein [DCF]). The DCF fluorescence signal was detected using a FACSCalibur flow cytometer (Becton Dickinson). For each group, 30 000 events were collected and data were analysed using FlowJo software (7.6.1).
| Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.01. All data are expressed as the mean AE SEM. Differences among multiple groups were assessed using one-way ANOVA, and differences between 2 groups were assessed using Student's t test. A P-value of <.05 was considered statistically significant. All experiments were conducted more than 3 times.
3 | RESULTS 3.1 | The IL-17A receptor is expressed on mouse podocytes IL-17A binds the IL-17 receptor to trigger downstream signalling. The functional IL-17A receptor is a heteromeric complex comprising IL-17RA and IL-17RC. 13 To verify the expression of IL-17A receptor on mouse podocytes, we detected IL-17RA and IL-17RC mRNA by RT-PCR (Figure 1A) . The data showed that mRNA encoding IL-17A receptor was persistently translated. Moreover, IL-17 receptor (CD217) expression was confirmed by flow cytometry ( Figure 1B) . Thus, IL-17 receptor is continuously expressed on mouse podocytes.
| IL-17A activates the NLRP3 inflammasome in podocytes
To examine the role of IL-17A on the NLRP3 inflammasome activation, the mRNA expression of NLRP3 and caspase-1 was measured. The data showed IL-17A could upregulate the expression of NLRP3 and caspase-1 in doseand time-dependently ( Figure S1 ). To further validate whether IL-17A activates the NLRP3 inflammasome in podocytes, we cultured podocytes with IL-17A (100 ng/ mL) for 48 hours. The results revealed marked upregulation of NLRP3 and caspase-1 expression when compared with that in the control group (Figure 2A-C) . Moreover, we measured IL-1b secretion and caspase-1 activity. The data showed that IL-1b secretion and caspase-1 activity were higher in the IL-17A group ( Figure 2D,E) . Taken together, the data suggest that IL-17A activates the NLRP3 inflammasome in podocytes.
| IL-17A induces intracellular ROS in podocytes
To explore the potential mechanism by which IL-17A activates the NLRP3 inflammasome in podocytes, intracellular
ROS was detected by flow cytometry. Intracellular ROS production in IL-17A group was higher than that in the control group (P < .05), indicating that IL-17A may act as an inducer of intracellular ROS ( Figure 3 ). To further clarify the role of IL-17A in the production of intracellular ROS, the IL-17 receptor was neutralized with a specific antibody (0.9 lg/mL) prior to exposure to IL-17A. The level of intracellular ROS in the IL-17RA group was significantly lower than that in the IL-17A group (Figure 3) . Thus, the data suggest that IL-17A induces ROS production in podocytes by binding to the IL-17 receptor on the cell surface.
| Activation of the NLRP3 inflammasome is blocked by NAC
ROS may activate the NLRP3 inflammasome by triggering release of the ROS-sensitive NLRP3 ligand thioredoxininteracting protein (TXNIP) from its inhibitor thioredoxin (TRX). 14 Thus, we used NAC, a scavenger of oxygen-free radicals, in the next round of experiments. As expected, treatment with NAC (10 lmol/L) led to a significant reduction in intracellular ROS (compare the IL-17A + NAC group with the IL-17A only group in Figure 3) . Meanwhile, the increased levels of caspase-1 activity and IL-1b secretion caused by exposure to IL17A were significantly lower in the presence of ROS scavenger NAC ( Figure 2F ,G).
To further verify increased secretion of IL-1b due to the activity caspase-1, we added a caspase-1 inhibitor (Z-YVAD-fmk) to the experiments. The results showed a clear reduction in caspase-1 activity and IL-1b levels in the cell supernatant ( Figure 2F ,G). Taken together, these results suggest that activation of the NLRP3 inflammasome and increased IL-1b secretion in IL-17A-treated podocytes can be blocked by NAC or a caspase-1 inhibitor.
| NAC or a caspase-1 inhibitor protects IL-17A-treated podocytes from injury by inhibiting NLRP3 inflammasome activation
Aberrant activation of the NLRP3 inflammasome has been implicated in the pathogenesis of diabetic nephropathy and ischaemia/reperfusion injury to the kidney. 10, 15, 16 To further clarify the potential mechanism underlying IL-17A-mediated podocyte injury, we examined the expression of desmin and podocin. Podocin, encoded by NPHS2, is a raft-associated component of glomerular foot processes; mutation of podocin can cause nephrotic syndrome in children. 17 Desmin is a marker of proteinuria in early nephrotic syndrome and is upregulated in injured podocytes. 18 Here, we found that IL-17A increased desmin expression and impaired podocin expression ( Figure 4A,B) . In addition, stress fibres in IL-17A-treated cells were disrupted, indicating rearrangement of F-actin (Figure 4Ca,Cb) . IL-17A-treated cells was measured using a colorimetric assay kit. E, IL-1b secretion by control and IL-17A-treated cells was measured in an ELISA. F, Podocytes were pretreated for 1 h with NAC or a caspase-1 inhibitor before exposure to IL-17A. Caspase-1 activity was then measured in all 4 groups. G, IL-1b secretion was measured in all 4 groups. *P < .05, **P < .01 and ***P < .001: IL-17A group vs CTL group; #P < .05, ##P < .01: IL-17A + NAC group vs IL-17A group; ▲P < .05, ▲▲P < .01: IL-17A + YVAD group vs IL-17A group
As outlined above, ROS activates the NLRP3 inflammasome and IL-17A significantly increases ROS levels in podocytes, a process blocked by the antioxidant NAC. To further investigate the protective role of NAC in IL-17A-treated podocytes, we examined NAC-treated cells for the expression of desmin and podocin. NAC-treated cells showed marked downregulation of desmin expression and upregulation of podocin expression when compared with cells treated with IL-17A ( Figure 4A,B) . Also, scavenging of intracellular ROS by NAC restored the normal microfilament-like structure and polarity of stress fibres (Figure 4Cc) .
ROS activates multiple signals (eg the p38 pathway) to induce cell injury and promote autophagy. 19, 20 To verify the role of caspase-1 in IL-17A-induced podocyte injury, we exposed cells to a caspase-1 inhibitor (Z-YVAD-fmk). Inhibiting caspase-1 activity increased expression of podocin and reduced expression of desmin (compare the YVAD group with the IL-17A group in Figure 4A ,B). F-actin in YVAD-treated cells was gathered into bundles to form stress fibres with normal polarity (Figure 4Cd ).
| DISCUSSION
PNS, the most common CKD in children, manifests as massive proteinuria and hypoalbuminemia. The Th17/IL-17A axis is thought to play a role in the pathogenesis of the disease. 5, 6 However, the mechanism by which IL-17A
participates in the development of proteinuria is unclear. Here, we found that IL-17A induced IL-1b secretion by activating the NLRP3 inflammasome, suggesting a potential role in the pathogenesis of PNS. IL-17A, mainly released from Th17 cells and cd T cells, plays a crucial role in mediating immune function via the IL-17A-IL-17R axis. It contributes to immune-related diseases through recruiting neutrophils accumulation and stimulating the release of proinflammatory cytokines neutrophils, macrophages and resident tissue cells. Here, we found that the IL-17A receptor was persistently expressed on the surface of mouse podocytes in vitro (Figure 1) , suggesting podocyte also was the potential target cell of IL-17A in immune-involved kidney diseases. Moreover, we also showed that intracellular ROS levels increased when podocytes were treated with IL-17A, but F I G U R E 3 Level of intracellular ROS was detected by flow cytometry. Podocytes were pretreated for 1 h with NAC or an IL-17 receptor antibody before exposure to IL-17A. Intracellular ROS was measured using an oxidation-sensitive fluorescent probe, DCFH-DA, which is oxidized to DCF in the presence of ROS. **P < .01: IL-17A group vs CTL; #P < .05: IL-17RA + NAC group vs IL-17A group; ▲P < .05: IL-17A + NAC group vs IL-17A group F I G U R E 4 Activation of the NLRP3 inflammasome results in podocyte injury. A, Expression of podocin and desmin was detected by Western blotting. B, Immunofluorescence analysis of podocin and desmin expression. C, F-actin structure was assessed using FITC-labelled phalloidin. *P < .05, **P < .01 and ***P < .001: IL-17A group vs CTL; ##P < .01 and ###P < .001: IL-17A + NAC group vs IL-17A group; ▲▲P < .01 and ▲▲▲P < .001: IL-17A + YVAD group vs IL-17A group fell significantly when the IL-17A receptor was blocked in advance ( Figure 3) . Taken together, these results indicate that IL-17A promotes generation of intracellular ROS by binding the IL-17A receptor on the surface of podocytes, suggesting IL-17A might directly induce podocyte injury through promoting intracellular ROS production. Consistent with these results, Huang et al showed that IL-17A plays a role in the ROS-dependent proliferation and differentiation of human mesenchymal stem cells.
NLRP3 inflammasome is a multiprotein complex that activates caspase 1, leading to maturation and secretion of IL-1b and IL-18. The inflammasome can be activated by various danger signals, such as high glucose concentrations or hyperhomocysteinemia, and be involved in the pathogenesis of diseases. 10, 11 To verify the hypothesis that IL-17A was the trigger of NLRP3 inflammasome activation and participates in podocytes injury, we cultured podocyte with IL-17A in vitro. We found that the expression of NLRP3 and caspase-1 was upregulated in podocytes exposed to IL-17A (Figure 2A-C) . Meanwhile, caspase-1 activity and IL-1b secretion increased upon exposure to IL-17A ( Figure 2D ,E), indicating that IL-17A activates the NLRP3 inflammasome in podocytes.
Up to now, 3 models of NLRP3 inflammasome activation have been proposed: the channel model, the lysosome rupture model and the ROS model and the role of ROS on the NLRP3 inflammasome activation was widely researched. 9, 14 Here, caspase-1 activity and IL-1b secretion were reduced by NAC, a scavenger of intracellular ROS, and decreased by caspase-1 inhibitor Z-YVAD-fmk ( Figure 2F ,G). Combined with previously mentioned data, these findings suggest that IL-17A induces secretion of IL-1b by activating the NLRP3 inflammasome via ROS generation. Furthermore, Abais et al 11 confirmed that upregulation of intracellular ROS was the main mechanism underlying activation of the NLRP3 inflammasome in hyperhomocysteinemia. IL-17A is a proinflammatory cytokine involved in kidney disease. 3 In vitro, IL-17A promotes podocyte apoptosis and downregulates phosphor-nephrin levels in podocytes.
5,7
However, we also found that expression of podocin decreased, while expression of desmin increased, when podocytes were treated with IL-17A ( Figure 4A,B) . Meanwhile, F-actin was disrupted into short fibres ( Figure 4C ). This indicates that IL-17A injures podocytes. Recent studies show that IL-17A may play a role in the pathogenesis of liver fibrosis and age-related macular degeneration via the NLRP3 inflammasome. 21, 22 Here, we showed that blocking NLRP3 activation (with NAC) or inhibiting caspase-1 activity (with Z-YVAD-fmk) led to upregulation of podocin and downregulation of desmin. Moreover, F-actin structure was restored. Taken together, the results suggest that IL-17A also induces podocyte injury by activating the NLRP3 inflammasome in vitro. Moreover, Zofia et al 23 confirmed that podocytes are the major IL-1b-secreting cell among kidney cells, and NLRP3 inflammasome activation is main molecular mechanism of maturation and secretion of IL-1b. In a previous study, we showed that IL-1b aggravates lipid-induced podocyte and mesangial cell injury during PNS by disrupting SREBP2-SCAP-LDL receptor signalling and inducing endoplasmic reticulum stress 24, 25 This supports the notion that IL-17A induces podocyte injury by inducing secretion of IL-1b via activation of the NLRP3 inflammasome. However, the conclusion was mainly confirmed by IL-17A-induced podocyte injury model in vitro, and there was still lack of adequate direct reference to clinical kidney diseases. Therefore, we still need to do more experiments to confirm the causality between IL-17A and NLRP3 inflammasome in vivo by human immune-related renal biopsy tissue or immunerelated kidney disease animal model in the future.
In conclusion, the results presented herein showed that IL-17A participates in podocyte injury by increasing IL-1b secretion through ROS-NLRP3 inflammasome-caspase-1 pathway.
